Skip to main content
Premium Trial:

Request an Annual Quote

Luminex to Report Greater Revenue, Smaller Loss for Q3 Than Expected

NEW YORK, Oct. 11 – Luminex said on Thursday that a surprising surge in sales during the third-quarter will help the company report greater-than-expected revenues and a leaner loss than Wall Street had forecast for the period.

The Austin, Tex.-based bead-array developer said in a statement that revenues for the quarter ended Sept. 30 would be about $6.2 million, exceeding the $6.1 million offered by an analysts’ consensus estimate.

Luminex also plans to announce a loss of 13 cents per share, compared with the loss of 18 cents forecast by an analyst consensus estimate.

The company, which plans to report its results after the market closes on Oct. 18, had been expected to lose between 16 cents and 19 cents per share in the third quarter, according to a survey of five analysts by Thomson Financial/First Call. Their consensus forecast was a loss of 18 cents.

Luminex is known chiefly for its LabMap technology, which beside genomics and proteomics research is used in pharmaceutical drug discovery, clinical diagnostics, and biomedical research.

Last month, the American Society of Histocompatibility and Immunogenetics cleared Orchid Biosciences to perform human leukocyte antigen testing using the LabMap platform. Orchid becomes the first firm to be certified to perform the testing with the LabMap technology.

Orchid said on Sept. 19 it plans to use the HLA testing to determine the potential for tissue or organ compatibility in single-sample testing and donor recruitment drives. The platform may also help determine whether a patient can accept donations of certain types of stem cells.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.